Selected research
Industry Growth & Trends
Global Mesalamine API Industry Growth and Trends Forecast to 2032
Market perspective
The global Mesalamine API market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Mesalamine API is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Mesalamine API is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Mesalamine API is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Mesalamine API include Cambrex Corporation, Chemi SpA, Corden Pharma Bergamo, CTX Lifescience, Divis Laboratories, Erregierre SpA, Ipca Laboratories, Ishita Active Pharma Ingredients and Lasa Loboratory, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Mesalamine API market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Mesalamine API market size, estimates, and forecasts are presented in terms of sales volume (t) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Mesalamine API market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Mesalamine API.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading manufacturers in the global Mesalamine API market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Mesalamine API Market by Company
Cambrex Corporation
Chemi SpA
Corden Pharma Bergamo
CTX Lifescience
Divis Laboratories
Erregierre SpA
Ipca Laboratories
Ishita Active Pharma Ingredients
Lasa Loboratory
PharmaZell
Syntese A/S
Hangzhou Brother
Lianyungang Fengheng Biopharm
YC Biotech (Jiangsu)
Mesalamine API Segment by Type
Purity ≥ 99%
Purity ≥ 98%
Purity ≥ 97%
Mesalamine API Segment by Application
Suppository
Tablets
Granule
Capsules
Enema
Others
Mesalamine API Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mesalamine API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mesalamine API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mesalamine API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Mesalamine API manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Mesalamine API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Purity ≥ 99%
- Purity ≥ 98%
- Purity ≥ 97%
Applications
- Suppository
- Tablets
- Granule
- Capsules
- Enema
- Others
Companies covered
- Cambrex Corporation
- Chemi SpA
- Corden Pharma Bergamo
- CTX Lifescience
- Divis Laboratories
- Erregierre SpA
- Ipca Laboratories
- Ishita Active Pharma Ingredients
- Lasa Loboratory
- PharmaZell
- Syntese A/S
- Hangzhou Brother
- Lianyungang Fengheng Biopharm
- YC Biotech (Jiangsu)
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Mesalamine API Market Size Estimates and Forecasts (2021-2032)
- 1.2.2 Global Mesalamine API Sales Estimates and Forecasts (2021-2032)
- 1.3 Mesalamine API Market by Type
- 1.3.1 Purity ≥ 99%
- 1.3.2 Purity ≥ 98%
- 1.3.3 Purity ≥ 97%
- 1.4 Global Mesalamine API Market Size by Type
- 1.4.1 Global Mesalamine API Market Size Overview by Type (2021-2032)
- 1.4.2 Global Mesalamine API Historic Market Size Review by Type (2021-2026)
- 1.4.3 Global Mesalamine API Forecasted Market Size by Type (2027-2032)
- 1.5 Key Regions Market Size by Type
- 1.5.1 North America Mesalamine API Sales Breakdown by Type (2021-2026)
- 1.5.2 Europe Mesalamine API Sales Breakdown by Type (2021-2026)
- 1.5.3 Asia-Pacific Mesalamine API Sales Breakdown by Type (2021-2026)
- 1.5.4 South America Mesalamine API Sales Breakdown by Type (2021-2026)
- 1.5.5 Middle East and Africa Mesalamine API Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
- 2.1 Mesalamine API Industry Trends
- 2.2 Mesalamine API Industry Drivers
- 2.3 Mesalamine API Industry Opportunities and Challenges
- 2.4 Mesalamine API Industry Restraints
3 Market Competitive Landscape by Company
- 3.1 Global Top Players by Mesalamine API Revenue (2021-2026)
- 3.2 Global Top Players by Mesalamine API Sales (2021-2026)
- 3.3 Global Top Players by Mesalamine API Price (2021-2026)
- 3.4 Global Mesalamine API Industry Company Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Mesalamine API Major Company Production Sites & Headquarters
- 3.6 Global Mesalamine API Company, Product Type & Application
- 3.7 Global Mesalamine API Company Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Mesalamine API Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Mesalamine API Players Market Share by Revenue in 2025
- 3.8.3 2025 Mesalamine API Tier 1, Tier 2, and Tier 3
4 Mesalamine API Regional Status and Outlook
- 4.1 Global Mesalamine API Market Size and CAGR by Region: 2021 VS 2025 VS 2032
- 4.2 Global Mesalamine API Historic Market Size by Region
- 4.2.1 Global Mesalamine API Sales in Volume by Region (2021-2026)
- 4.2.2 Global Mesalamine API Sales in Value by Region (2021-2026)
- 4.2.3 Global Mesalamine API Sales (Volume & Value), Price and Gross Margin (2021-2026)
- 4.3 Global Mesalamine API Forecasted Market Size by Region
- 4.3.1 Global Mesalamine API Sales in Volume by Region (2027-2032)
- 4.3.2 Global Mesalamine API Sales in Value by Region (2027-2032)
- 4.3.3 Global Mesalamine API Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Mesalamine API by Application
- 5.1 Mesalamine API Market by Application
- 5.1.1 Suppository
- 5.1.2 Tablets
- 5.1.3 Granule
- 5.1.4 Capsules
- 5.1.5 Enema
- 5.1.6 Others
- 5.2 Global Mesalamine API Market Size by Application
- 5.2.1 Global Mesalamine API Market Size Overview by Application (2021-2032)
- 5.2.2 Global Mesalamine API Historic Market Size Review by Application (2021-2026)
- 5.2.3 Global Mesalamine API Forecasted Market Size by Application (2027-2032)
- 5.3 Key Regions Market Size by Application
- 5.3.1 North America Mesalamine API Sales Breakdown by Application (2021-2026)
- 5.3.2 Europe Mesalamine API Sales Breakdown by Application (2021-2026)
- 5.3.3 Asia-Pacific Mesalamine API Sales Breakdown by Application (2021-2026)
- 5.3.4 South America Mesalamine API Sales Breakdown by Application (2021-2026)
- 5.3.5 Middle East and Africa Mesalamine API Sales Breakdown by Application (2021-2026)
6 Company Profiles
- 6.1 Cambrex Corporation
- 6.1.1 Cambrex Corporation Company Information
- 6.1.2 Cambrex Corporation Business Overview
- 6.1.3 Cambrex Corporation Mesalamine API Sales, Revenue and Gross Margin (2021-2026)
- 6.1.4 Cambrex Corporation Mesalamine API Product Portfolio
- 6.1.5 Cambrex Corporation Recent Developments
- 6.2 Chemi SpA
- 6.2.1 Chemi SpA Company Information
- 6.2.2 Chemi SpA Business Overview
- 6.2.3 Chemi SpA Mesalamine API Sales, Revenue and Gross Margin (2021-2026)
- 6.2.4 Chemi SpA Mesalamine API Product Portfolio
- 6.2.5 Chemi SpA Recent Developments
- 6.3 Corden Pharma Bergamo
- 6.3.1 Corden Pharma Bergamo Company Information
- 6.3.2 Corden Pharma Bergamo Business Overview
- 6.3.3 Corden Pharma Bergamo Mesalamine API Sales, Revenue and Gross Margin (2021-2026)
- 6.3.4 Corden Pharma Bergamo Mesalamine API Product Portfolio
- 6.3.5 Corden Pharma Bergamo Recent Developments
- 6.4 CTX Lifescience
- 6.4.1 CTX Lifescience Company Information
- 6.4.2 CTX Lifescience Business Overview
- 6.4.3 CTX Lifescience Mesalamine API Sales, Revenue and Gross Margin (2021-2026)
- 6.4.4 CTX Lifescience Mesalamine API Product Portfolio
- 6.4.5 CTX Lifescience Recent Developments
- 6.5 Divis Laboratories
- 6.5.1 Divis Laboratories Company Information
- 6.5.2 Divis Laboratories Business Overview
- 6.5.3 Divis Laboratories Mesalamine API Sales, Revenue and Gross Margin (2021-2026)
- 6.5.4 Divis Laboratories Mesalamine API Product Portfolio
- 6.5.5 Divis Laboratories Recent Developments
- 6.6 Erregierre SpA
- 6.6.1 Erregierre SpA Company Information
- 6.6.2 Erregierre SpA Business Overview
- 6.6.3 Erregierre SpA Mesalamine API Sales, Revenue and Gross Margin (2021-2026)
- 6.6.4 Erregierre SpA Mesalamine API Product Portfolio
- 6.6.5 Erregierre SpA Recent Developments
- 6.7 Ipca Laboratories
- 6.7.1 Ipca Laboratories Company Information
- 6.7.2 Ipca Laboratories Business Overview
- 6.7.3 Ipca Laboratories Mesalamine API Sales, Revenue and Gross Margin (2021-2026)
- 6.7.4 Ipca Laboratories Mesalamine API Product Portfolio
- 6.7.5 Ipca Laboratories Recent Developments
- 6.8 Ishita Active Pharma Ingredients
- 6.8.1 Ishita Active Pharma Ingredients Company Information
- 6.8.2 Ishita Active Pharma Ingredients Business Overview
- 6.8.3 Ishita Active Pharma Ingredients Mesalamine API Sales, Revenue and Gross Margin (2021-2026)
- 6.8.4 Ishita Active Pharma Ingredients Mesalamine API Product Portfolio
- 6.8.5 Ishita Active Pharma Ingredients Recent Developments
- 6.9 Lasa Loboratory
- 6.9.1 Lasa Loboratory Company Information
- 6.9.2 Lasa Loboratory Business Overview
- 6.9.3 Lasa Loboratory Mesalamine API Sales, Revenue and Gross Margin (2021-2026)
- 6.9.4 Lasa Loboratory Mesalamine API Product Portfolio
- 6.9.5 Lasa Loboratory Recent Developments
- 6.10 PharmaZell
- 6.10.1 PharmaZell Company Information
- 6.10.2 PharmaZell Business Overview
- 6.10.3 PharmaZell Mesalamine API Sales, Revenue and Gross Margin (2021-2026)
- 6.10.4 PharmaZell Mesalamine API Product Portfolio
- 6.10.5 PharmaZell Recent Developments
- 6.11 Syntese A/S
- 6.11.1 Syntese A/S Company Information
- 6.11.2 Syntese A/S Business Overview
- 6.11.3 Syntese A/S Mesalamine API Sales, Revenue and Gross Margin (2021-2026)
- 6.11.4 Syntese A/S Mesalamine API Product Portfolio
- 6.11.5 Syntese A/S Recent Developments
- 6.12 Hangzhou Brother
- 6.12.1 Hangzhou Brother Company Information
- 6.12.2 Hangzhou Brother Business Overview
- 6.12.3 Hangzhou Brother Mesalamine API Sales, Revenue and Gross Margin (2021-2026)
- 6.12.4 Hangzhou Brother Mesalamine API Product Portfolio
- 6.12.5 Hangzhou Brother Recent Developments
- 6.13 Lianyungang Fengheng Biopharm
- 6.13.1 Lianyungang Fengheng Biopharm Company Information
- 6.13.2 Lianyungang Fengheng Biopharm Business Overview
- 6.13.3 Lianyungang Fengheng Biopharm Mesalamine API Sales, Revenue and Gross Margin (2021-2026)
- 6.13.4 Lianyungang Fengheng Biopharm Mesalamine API Product Portfolio
- 6.13.5 Lianyungang Fengheng Biopharm Recent Developments
- 6.14 YC Biotech (Jiangsu)
- 6.14.1 YC Biotech (Jiangsu) Company Information
- 6.14.2 YC Biotech (Jiangsu) Business Overview
- 6.14.3 YC Biotech (Jiangsu) Mesalamine API Sales, Revenue and Gross Margin (2021-2026)
- 6.14.4 YC Biotech (Jiangsu) Mesalamine API Product Portfolio
- 6.14.5 YC Biotech (Jiangsu) Recent Developments
7 North America by Country
- 7.1 North America Mesalamine API Sales by Country
- 7.1.1 North America Mesalamine API Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.1.2 North America Mesalamine API Sales by Country (2021-2026)
- 7.1.3 North America Mesalamine API Sales Forecast by Country (2027-2032)
- 7.2 North America Mesalamine API Market Size by Country
- 7.2.1 North America Mesalamine API Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2.2 North America Mesalamine API Market Size by Country (2021-2026)
- 7.2.3 North America Mesalamine API Market Size Forecast by Country (2027-2032)
8 Europe by Country
- 8.1 Europe Mesalamine API Sales by Country
- 8.1.1 Europe Mesalamine API Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.1.2 Europe Mesalamine API Sales by Country (2021-2026)
- 8.1.3 Europe Mesalamine API Sales Forecast by Country (2027-2032)
- 8.2 Europe Mesalamine API Market Size by Country
- 8.2.1 Europe Mesalamine API Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2.2 Europe Mesalamine API Market Size by Country (2021-2026)
- 8.2.3 Europe Mesalamine API Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
- 9.1 Asia-Pacific Mesalamine API Sales by Country
- 9.1.1 Asia-Pacific Mesalamine API Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.1.2 Asia-Pacific Mesalamine API Sales by Country (2021-2026)
- 9.1.3 Asia-Pacific Mesalamine API Sales Forecast by Country (2027-2032)
- 9.2 Asia-Pacific Mesalamine API Market Size by Country
- 9.2.1 Asia-Pacific Mesalamine API Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2.2 Asia-Pacific Mesalamine API Market Size by Country (2021-2026)
- 9.2.3 Asia-Pacific Mesalamine API Market Size Forecast by Country (2027-2032)
10 South America by Country
- 10.1 South America Mesalamine API Sales by Country
- 10.1.1 South America Mesalamine API Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.1.2 South America Mesalamine API Sales by Country (2021-2026)
- 10.1.3 South America Mesalamine API Sales Forecast by Country (2027-2032)
- 10.2 South America Mesalamine API Market Size by Country
- 10.2.1 South America Mesalamine API Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2.2 South America Mesalamine API Market Size by Country (2021-2026)
- 10.2.3 South America Mesalamine API Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
- 11.1 Middle East and Africa Mesalamine API Sales by Country
- 11.1.1 Middle East and Africa Mesalamine API Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.1.2 Middle East and Africa Mesalamine API Sales by Country (2021-2026)
- 11.1.3 Middle East and Africa Mesalamine API Sales Forecast by Country (2027-2032)
- 11.2 Middle East and Africa Mesalamine API Market Size by Country
- 11.2.1 Middle East and Africa Mesalamine API Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2.2 Middle East and Africa Mesalamine API Market Size by Country (2021-2026)
- 11.2.3 Middle East and Africa Mesalamine API Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
- 12.1 Mesalamine API Value Chain Analysis
- 12.1.1 Mesalamine API Key Raw Materials
- 12.1.2 Key Raw Materials Price
- 12.1.3 Raw Materials Key Suppliers
- 12.1.4 Manufacturing Cost Structure
- 12.1.5 Mesalamine API Production Mode & Process
- 12.2 Mesalamine API Sales Channels Analysis
- 12.2.1 Direct Comparison with Distribution Share
- 12.2.2 Mesalamine API Distributors
- 12.2.3 Mesalamine API Customers
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
- 14.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst